Table 4.
Correlation of LYMR/NLR with clinicopathological factors (n=92)
| Variables | LYMR
|
P value | NLR
|
P-value | ||
|---|---|---|---|---|---|---|
| Low | High | Low | High | |||
| Gender | ||||||
| Male | 39 (63.9) | 22 (36.1) | 0.37 | 20 (32.8) | 41 (67.2) | 0.353 |
| Female | 22 (73.3) | 8 (26.7) | 7 (23.3) | 23 (76.7) | ||
| Age (years) | ||||||
| <60 | 40 (66.7) | 20 (33.3) | 0.918 | 17 (28.3) | 43 (71.7) | 0.698 |
| ≥60 | 21 (67.7) | 10 (32.3) | 10 (32.3) | 21 (67.7) | ||
| CD8+ TIL | ||||||
| High | 14 (60.9) | 9 (39.1) | 0.467 | 7 (30.4) | 16 (69.6) | 0.926 |
| Low | 47 (69.1) | 21 (30.9) | 20 (29.4) | 48 (70.6) | ||
| Pre-CRT CEA | ||||||
| >5 | 25 (67.6) | 12 (32.4) | 0.878 | 10 (27.0) | 27 (73.0) | 0.616 |
| ≤5 | 33 (66.0) | 17 (34.0) | 16 (32.0) | 34 (68.0) | ||
| Chemo cyclesa | ||||||
| 3–4 | 44 (62.0) | 27 (38.0) | 0.096 | 25 (35.2) | 46 (64.8) | 0.057 |
| 1–2 | 17 (85.0) | 3 (15.0) | 2 (10.0) | 18 (90.0) | ||
Note:
a
Cycles of concurrent chemotherapy received.
Abbreviations: LYMR, lymphocyte ratio; NLR, neutrophil–lymphocyte ratio; TIL, tumor-infiltrating lymphocyte; CRT, chemoradiotherapy; CEA, carcinoembryonic antigen.